Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female, age above or equal to 18 years at the time of signing the informed consent. * Patients diagnosed with Type 2 Diabetes Mellitus (T2DM). * Patients who were not achieving optimal glycaemic control and who required intensification of antidiabetic treatment and Ryzodeg was the treatment of choice. * Available and documented HbA1c value at less or equal to 12 weeks prior to initiation of Ryzodeg® treatment and end of study within the study windows. * Available and documented follow up time of at least 52 weeks with 26 weeks follow-up prior to and after initiation of Ryzodeg®. * The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. Exclusion Criteria: * Previous participation in this study. Participation is defined as signed informed consent. * Participation in any clinical study of an approved or non-approved investigational medicinal product within 26 weeks before and after initiation of treatment with Ryzodeg®. * Having been previously treated with Ryzodeg® prior to study start. * Female who were pregnant or breast-feeding during the study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.